Loading stock data…
Theravance Biopharma (TBPH)
$17.06-0.02 (-0.12%)
Market ClosedLast close Sep 8
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Theravance Biopharma, Inc. in the Healthcare sector is trading at $17.06 with a market capitalization of $849M. Wall Street consensus targets $17.67 (3 analysts), implying a +3.6% move over the next 12 months. The stock is currently 19% below its 52-week high of $21.03, remaining 1.3% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. Risk note: RSI 70 is overbought against a weak tape. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 70 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $17.70M↓ | $45.89M↑ | $19.99M↓ | $26.20M↑ | $15.39M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.85M↓ | $20.01M↑ | -$6.46M↓ | -$2.73M↑ | -$14.43M |
| Net Income | -$4.93M↓ | $61.02M↑ | $3.62M↓ | $54.84M↑ | -$13.58M |
Peer Comparison
JNJUNHPFE
Fundamentals
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary dise...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$848.56M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
39.42%
Volume
Today's trading volume
251,316
Recent News
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.
electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates
electroCore (ECOR) delivered earnings and revenue surprises of +19.51% and +0.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of +12.50% and +6.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of +26.11% and +6.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks (ZYME) Stock Looks Fully Valued Despite Its 205% Three Year Run
Zymeworks stock has delivered a very strong 204.7% return over the past three years, yet the current valuation checks and market multiples suggest the shares may now be pricing in a lot of good news. The 204.7% three year return points to investors already paying up for Zymeworks' progress and future potential. The planned US$929m cash acquisition of Theravance Biopharma may support longer term revenue and earnings. However, integration execution and the funding structure can add risk to how...